November 9, 2023 11:09 AM ESTUpdated November 10, 03:48 PM
News Briefing

In­tel­lia plans to file IND for AATD tri­al next year; As­cid­i­an rais­es $40M

Jaimy Lee

Deputy Editor

Lei Lei Wu

News Reporter

In­tel­lia aims to start AATD tri­al next year: The gene edit­ing com­pa­ny an­nounced Thurs­day that it plans to file an ap­pli­ca­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Cor­rect­ed: Trump's broad tar­iffs could mark a 'dou­ble wham­my' for phar­ma af­ter FDA cuts

Day af­ter mass FDA fir­ings, new com­mis­sion­er ad­dress­es re­main­ing staff, fo­cus­ing on 'MA­HA' vi­sion

FDA cuts stir buy­er’s re­morse for some bio­phar­ma lead­ers, once ex­cit­ed by Trump

Q&A: John Crow­ley warns biotech is 'dan­ger­ous­ly close' to break­ing, as tar­iff threat, mar­kets bat­ter in­dus­try

Roche says Ocre­vus failed Phase 3 study; Sanofi li­cens­es au­toim­mune as­set from Nurix

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times